Research
Teen and Young Adult Survey Extended Through January 21st
Are you or a family member between the ages of 12 and 25? Do you want to share your opinion on living with SMA and […]
Read More ›Cure SMA Announces Expanded Phase 3 of SMA Industry Collaboration
Cure SMA is pleased to announce the launch of an expanded Phase 3 of our SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted […]
Read More ›December Webinar on SMA Treatments and Clinical Trials Now Available Online
A recording of the December 13th webinar updating the community on SMA treatments and clinical trials is now available online. A PDF of the webinar […]
Read More ›2018 Research Year-in-Review
Over our past fiscal year—from July 1, 2017, to June 30, 2018—Cure SMA has funded over $5 million in new research funding. This funding will be […]
Read More ›Cure SMA Funding Leads to 16 New Research Publications in 2018
An important goal of our research funding strategy is to share scientific findings with the broader scientific community. Scientists who receive Cure SMA funding often […]
Read More ›Biogen Issues Q4 Community Statement on Spinraza
Bigoen has provided the below community statement on Spinraza. Dear Members of the SMA community, As we approach the two-year anniversary of the U.S. Food […]
Read More ›AveXis Issues Community Statement on BLA Acceptance
AveXis has provided the following community statement on the BLA submission and acceptance for their investigational therapy, AVXS-101 – now known as ZOLGENSMA®. Dear SMA […]
Read More ›Fall 2018 Issue of Compass Now Available
The fall 2018 issue of Compass is now available online. This issue of Compass covers the SMA Care Center Network and its goal of developing an […]
Read More ›Novartis Announces FDA Filing Acceptance and Priority Review for AVXS-101
Novartis today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for AVXS-101, now known as ZOLGENSMA® […]
Read More ›Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of SMA
Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the […]
Read More ›